Expertise in
56
conditions

Dr. Sayed M. Yossef

Gastroenterology
Office
250 Debartolo Pl Ste 3000, 
Boardman, OH 
Accepting New Patients
Expertise in
56
conditions
Office
250 Debartolo Pl Ste 3000, 
Boardman, OH 

Overview

Sayed Yossef is a Gastroenterologist practicing medicine in Boardman, Ohio.

Dr. Yossef is highly rated in 56 conditions, according to our data. His clinical expertise encompasses Bile Duct Obstruction, Lower Esophageal Ring, Benign Esophageal Stricture, Gastrectomy, and Endoscopy.

He is actively involved in clinical research, co-authoring 1 peer reviewed article and participating in 6 clinical trials. Dr. Yossef is currently accepting new patients.

Specialties

Gastroenterology

Licenses

Internal Medicine in OH

Hospital Affiliations

Mh St Elizabeth Youngstown Hospital
Hmhp St Elizabeth Boardman Health Center
Surgical Hospital At Southwoods

Languages Spoken

English
Arabic
Arabic - Jordanian

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
CareSource
  • HMO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medical Health
  • HMO
  • PPO
Medical Mutual
  • HMO
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
MetLife
  • PPO
Paramount
  • EPO
  • HMO
  • INDEMNITY
  • PPO
SummaCare
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 22 Less Insurance Carriers -

Locations

Office
250 Debartolo Pl Ste 3000, Boardman, OH 44512

Additional Areas of Focus

Dr. Yossef has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
Enrollment Status: Completed
Publish Date: May 13, 2026
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2026
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease
A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: January 21, 2026
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Enrollment Status: Completed
Publish Date: May 31, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
Enrollment Status: Completed
Publish Date: December 27, 2024
Intervention Type: Drug
Study Drugs: Mirikizumab, Ustekinumab
Study Phase: Phase 3
View 4 Less Clinical Trials

1 Total Publications

An Oral Formulation of the Probiotic, Bacillus subtilis HU58, Was Safe and Well Tolerated in a Pilot Study of Patients with Hepatic Encephalopathy.
An Oral Formulation of the Probiotic, Bacillus subtilis HU58, Was Safe and Well Tolerated in a Pilot Study of Patients with Hepatic Encephalopathy.
Journal: Evidence-based complementary and alternative medicine : eCAM
Published: November 03, 2019
Similar Doctors
Expertise in
27
conditions
Dr. Prashanthi N. Thota
Gastroenterology
Expertise in
27
conditions
Dr. Prashanthi N. Thota
Gastroenterology
Referral may be required

Cleveland Clinic Main Campus

9500 Euclid Avenue, 
Cleveland, OH 
 (59.5 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Prashanthi Thota is a Gastroenterologist practicing medicine in Cleveland, Ohio. Dr. Thota is highly rated in 27 conditions, according to our data. Her clinical expertise encompasses Barrett Esophagus, Achalasia, Hiatal Hernia, Endoscopy, and Colonoscopy. Dr. Thota is currently accepting new patients.

Expertise in
16
conditions
Dr. Miguel D. Regueiro
Gastroenterology
Expertise in
16
conditions
Dr. Miguel D. Regueiro
Gastroenterology
Referral may be required
Before you request

Cleveland Clinic Main Campus

2049 East 100th Street, 
Cleveland, OH 
 (59.3 miles away)
216-444-2200
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Miguel Regueiro is a Gastroenterologist practicing medicine in Cleveland, Ohio. Dr. Regueiro is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Crohn's Disease, Viral Gastroenteritis, Ulcerative Colitis, Ileostomy, and Colonoscopy. Dr. Regueiro is board certified in American Board Of Internal Medicine, 1997. Dr. Regueiro is currently accepting new patients.

Expertise in
25
conditions
Dr. Scott L. Gabbard
Gastroenterology
Expertise in
25
conditions
Dr. Scott L. Gabbard
Gastroenterology
Referral may be required
Before you request

Cleveland Clinic Main Campus

9500 Euclid Avenue, 
Cleveland, OH 
 (59.5 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Scott Gabbard is a Gastroenterologist practicing medicine in Cleveland, Ohio. Dr. Gabbard is highly rated in 25 conditions, according to our data. His clinical expertise encompasses Achalasia, Gastroesophageal Reflux Disease (GERD), Swallowing Difficulty, Endoscopy, and Gastrectomy. Dr. Gabbard is board certified in American Board Of Internal Medicine, 2012. Dr. Gabbard is currently accepting new patients.

Frequently Asked Questions about Dr. Sayed M. Yossef

How do I make an appointment with Dr. Sayed M. Yossef?

You can book an appointment with Dr. Sayed M. Yossef by calling their office at 234-287-6602. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Sayed M. Yossef a top-rated expert for Bile Duct Obstruction?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Sayed M. Yossef is classified as an Distinguished expert for Bile Duct Obstruction, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Sayed M. Yossef specialize in?

While Dr. Sayed M. Yossef is a Gastroenterology, they have specific expertise in Bile Duct Obstruction, Lower Esophageal Ring, and Benign Esophageal Stricture. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Gastroenterology.

Does Dr. Sayed M. Yossef participate in research or clinical trials?

Yes. Dr. Sayed M. Yossef has published 1 articles and abstracts on conditions like Bile Duct Obstruction. You can view a list of Dr. Sayed M. Yossef's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Sayed M. Yossef accept my insurance?

Dr. Sayed M. Yossef accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 234-287-6602 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Yossef's expertise for a condition
ConditionClose
    View All 18 Distinguished Conditions
    View All 38 Advanced Conditions
    View All 47 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile